Skip to content

Specialties
Clinical Updates
Medical News
iDoctor

Specialties
Clinical Updates
Medical News
iDoctor

Search for:

facebook.com
twitter.com
t.me
instagram.com
youtube.com

T-cell Engager

Home
T-cell Engager

$Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma$

Posted inHematology-Oncology news Oncology

Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma

Posted by

By MedXY 07/13/2026

Pavurutamab demonstrates manageable safety and encouraging efficacy in heavily pretreated relapsed/refractory multiple myeloma, showing an overall response rate of 46.5% and median progression-free survival of 16.8 months at the recommended dose.

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers

Posted innews Oncology Specialties

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers

Posted by

By MedXY 09/21/2025

Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.

Survival Estimates and Predictors in Genetic Frontotemporal Dementia: Insights from an International Retrospective Cohort Study
Impact of Maternal Third-Trimester TRAb Levels on Neonatal Thyroid Function and Early Childhood Neurodevelopment: Insights from a Bidirectional Cohort Study
Leveraging Polygenic Scores to Predict Diabetes Risk After Gestational Diabetes: Insights from a 30-Year Cohort Study
Distinguishing Partial Lipodystrophy from Cushing’s Syndrome: Clinical Overlaps and Diagnostic Challenges
Prior Authorization Suspension Boosts Access to Diabetes Technology and Improves Glycemic Control in Underserved Populations

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.

Sign in